NGT BioPharma Consultants
Due DiligenceA start-up

Diligence supporting a late-stage asset acquisition

Challenge

A start-up's late-stage asset was being evaluated for acquisition by a global technology firm, which needed a clear read on the asset.

Approach

NGT ran a data-driven analysis of the asset's development and regulatory standing to support the transaction.

Outcome

The analysis supported the start-up's late-stage asset acquisition by a global technology firm.

← All case studies

Bring NGT into your program

Tell us where your program stands and which disciplines you need. A member of the team will follow up.

Contact the team